Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) "After Multiple Oral Doses" in Healthy Volunteers

Parkinson Disease Clinical Trial

Official title:

Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) "After Multiple Oral Doses" in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02111330
• Other study ID #: IIBSP-PBF-2013-155
• Secondary ID: 2013-005035-25
• Status: Completed
• Phase: Phase 1
• First received: March 20, 2014
• Last updated: March 7, 2016
• Start date: March 2014
• Est. completion date: May 2014

Study information

• Verified date: March 2016
• Source: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Spanish Agency of Medicines
• Study type: Interventional

Clinical Trial Summary

Study to assess the safety and tolerability of three doses of PBF-509 (80 mg, 160 mg and 240 mg) after repeated (8 days) single daily oral dose administration in young male and female healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy male or females subjects, 18-45 years (inclusive) of age at the time of enrollment.

• Females must be of non-childbearing potential (i.e., surgically sterile) or have to use contraceptive measures (non-hormonal) such as condom, diaphragm or cervical/vault cap with spermicide. Males should agree to abstain from sexual intercourse with a female partner or agree to use a condom/spermicide, in addition to having their female partner use some contraceptive measures.

• Clinically acceptable blood pressure and pulse rate in supine and standing position. Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.

• Body weight within normal range (Quetelet's index between 19 and 26) expressed as weight (kg) / height (m2).

• Able to understand the nature of the study and comply with all their requirements.

• Free acceptance to participate in the study by obtains signed informed consent form approved by the Ethics Committee of the Hospital (CEIC).

Exclusion Criteria:

• History of serious adverse reactions or hypersensitivity to any drug.

• Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).

• Background or clinical evidence of chronic diseases.

• Acute illness two weeks before drug administration.

• Having undergone major surgery during the previous 6 months.

• Smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the administration of the study medication

• History of alcohol dependence or drug abuse in the last 5 years or daily consumption of alcohol > 40 g for men or 24 gr/day for women or high consumption of stimulating beverages (> 5 coffees, teas or coca cola drinks/ day)

• Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.

• Need of any prescription medication within 14 days prior to the administration of the drug and non prescription medication or herbal medicines within 7 days prior to the administration of the drug.

• Participation in other clinical trials during the previous 90 days in which an investigational drug or a commercially available drug was tested.

• Having donated blood during 4 weeks period before inclusion in the study.

• Existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.

• 12 lead ECG obtained at screening with PR = 220 msec, QRS = 120 msec and QTc = 440 msec, bradycardia (<50 bpm) or clinically significant minor ST wave changes or any other abnormal changes on the screening ECG that would interfere with measurement of the QT interval.

• Symptoms of a significant somatic or mental illness in the four week period preceding drug administration.

• History of hepatitis HBV and / or HCV and / or positive serology results which indicate the presence of hepatitis B surface antigen and / or detectable HCV ribonucleic acid (RNA).

• Positive results from the HIV serology.

• Clinically significant abnormal laboratory values (as determined by the Principal Investigator) at the screening evaluation.

• Positive results of the drugs at screening period or the day before starting treatment period. A minimum list of drugs that will be screened for include Amphetamines, Cocaine, Ethanol, Opiates, Cannabinoids and Benzodiazepines (positive results may be repeated at the discretion of the Principal Investigator).

• Known hypersensitivity to the study drug or the composition of the galenical form.

• History of psychiatric diseases or epileptic seizures

• Females with positive results from the pregnancy test or breast-feeding.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Drug:
• PBF-509

• Placebo

Locations

Country	Name	City	State
Spain	CIM Sant Pau - I.I.B. Sant Pau	Barcelona
Spain	Palobiofarma S.L. (molecule owner)	Mataró	Barcelona

Sponsors (2)

Lead Sponsor	Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Palo Biofarma, S.L

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Adverse Events		day 0-9	Yes
Secondary	Pharmacokinetic Profile Analysis (Plasma concentrations)		day 0-9	No